MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/cancers15010095

Медицинская библиотека · Cancers · 2022

Prospective Assessment of Tumour Burden and Bone Disease in Plasma Cell Dyscrasias Using DW-MRI and Exploratory Bone Biomarkers.

Agarwal Gaurav, Nador Guido, Varghese Sherin, Getu Hiwot, Palmer Charlotte, Watson Edmund, Pereira Claudio, Sallemi Germana, Partington Karen, Patel Neel, Soundarajan Rajkumar, Mills Rebecca, Brouwer Richard, Maritati Marina, Shah Aarti, Peppercorn Delia, Oppermann Udo, Edwards Claire M, Rodgers Christopher T, Javaid Muhammad Kassim, Gooding Sarah, Ramasamy Karthik

СтатьяПеревод в очереди

Аннотация

Novel biomarkers for tumour burden and bone disease are required to guide clinical management of plasma cell dyscrasias. Recently, bone turnover markers (BTMs) and Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) have been explored, although their role in the prospective assessment of multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) is unclear. Here, we conducted a pilot observational cohort feasibility study combining serum BTMs and DW-MRI in addition to standard clinical assessment. Fifty-five patients were recruited (14 MGUS, 15 smouldering MM, 14 new MM and 12 relapsed MM) and had DW-MRI and serum biomarkers (P1NP, CTX-1, ALP, DKK1, sclerostin, RANKL:OPG and BCMA) measured at baseline and 6-month follow-up. Serum sclerostin positively correlated with bone mineral density (r = 0.40-0.54). At baseline, serum BCMA correlated with serum paraprotein (r = 0.42) and serum DKK1 correlated with serum free light chains (r = 0.67); the longitudinal change in both biomarkers differed between International Myeloma Working Group (IMWG)-defined responders and non-responders. Myeloma Response Assessment and Diagnosis System (MY-RADS) scoring of serial DW-MRI correlated with conventional IMWG response criteria for measuring longitudinal changes in tumour burden. Overall, our pilot study suggests candidate radiological and serum biomarkers of tumour burden and bone loss in MM/MGUS, which warrant further exploration in larger cohorts to validate the findings and to better understand their clinical utility.

Для цитирования: Agarwal Gaurav, Nador Guido, Varghese Sherin, Getu Hiwot, Palmer Charlotte, Watson Edmund, Pereira Claudio, Sallemi Germana, Partington Karen, Patel Neel, Soundarajan Rajkumar, Mills Rebecca, Brouwer Richard, Maritati Marina, Shah Aarti, Peppercorn Delia, Oppermann Udo, Edwards Claire M, Rodgers Christopher T, Javaid Muhammad Kassim, Gooding Sarah, Ramasamy Karthik. Prospective Assessment of Tumour Burden and Bone Disease in Plasma Cell Dyscrasias Using DW-MRI and Exploratory Bone Biomarkers.. Cancers. 2022. DOI: 10.3390/cancers15010095.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.